Amnesty International puts numbers on inequality in access to vaccines around the world after the last warning, the umpteenth, of the United Nations about “obscenity” and “ethical failure” which means that the rich countries have already immunized the majority of their population while in Africa less than 10% are inoculated. The non-governmental organization analyzes the contribution of each pharmaceutical company that markets vaccines in equal distribution and identifies the least collaborative: Moderna and Pfizer-BioNTech.
“Justice and charity have failed to vaccinate”
The former has yet to deliver a “single dose to low-income countries” and most of its contribution to COVAX will last until 2022, according to the report. Double Dose of Inequality: Pharmaceutical Companies and the COVID-19 Vaccine Crisis.
Pfizer-BioNTech, with a large distribution in Spain, has delivered 99% of the doses to high-income or upper-middle-income countries. This means, for example, that “Sweden has received nine times more doses of Pfizer than all poor countries combined,” Amnesty International denounces. Only 8% of its production will go to COVAX. Moderna’s is even lower: 3.4%, the report points out.
The revenue forecast for these companies by the end of 2022 is $ 86 billion and $ 47,000, respectively.
The task force made up of the World Health Organization, the World Trade Organization, the International Monetary Fund and the World Bank set a goal of vaccinating 40% of the population in low- and lower-middle-income countries by the end of 2021 There are 100 days left for that and less than 10% of the citizens who inhabit these territories are fully vaccinated, recalls the NGO.
Several studies confirm that countries have not fulfilled their commitments. Less than 15% of the coronavirus vaccine doses that G7 nations said they would donate have been delivered to date, according to a report Posted by analytics company Airfinity.
Intense pressure triggered a meeting in Cornwall in June of the seven leaders of the world’s most advanced economies to agree immediate action against the huge inequality in global vaccination. Then they announced the direct donation of at least 870 million doses, and they promised to do it “as soon as possible”, with the purpose of delivering “at least half” by the end of 2021. They also said that they were going to “mainly channel them ” through of the COVAX mechanism, which tries to ensure an equitable distribution.
Faced with slowness and non-compliance, Amnesty International calls on governments and pharmaceutical companies to supply 2 billion vaccines in the three months that come to 82 countries to vaccinate 1.2 billion people with the full schedule. “Companies must distribute 50% of their production to these countries through the COVAX mechanism or other multilateral initiatives and the states must urgently distribute the hundreds of millions of surplus vaccines they have in their stocks. Only in this way can this gap be bridged”, the report warns.
Johnson and Johnson, which distributes Janssen’s single-dose vaccine, sold 79% of the batches to high- and upper-middle-income countries, but plans to deliver to COVAX and the African Union a number of doses corresponding to 53% of its deliveries before the end of the year. If this is fulfilled, the distribution would be rebalanced.
AstraZeneca, for its part, sells at cost and “has granted some voluntary licenses to other manufacturers,” although, Amnesty International stresses, “it has refused to openly share its knowledge and technology with the initiatives of the World Organization for Economic Development. Health”. The use of Novavax has not yet been approved, but the report states that “it plans to dedicate almost two thirds of its production to supply COVAX”: what it considers “a more responsible approach”.